Kepler Capital Sticks to Their Hold Rating for SAFRAN SA (0IU8)
In a report released on April 23, Aymeric Poulain from Kepler Capital maintained a Hold rating on SAFRAN SA (0IU8 – Research Report), with a price target of €258.00. The company's shares closed last Thursday at €220.90.
Stay Ahead of the Market:
Discover outperforming stocks and invest smarter with Top Smart Score Stocks.
Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener.
Poulain covers the Industrials sector, focusing on stocks such as Airbus Group SE, BAE Systems, and Rolls-Royce Holdings. According to TipRanks, Poulain has an average return of 14.1% and a 64.63% success rate on recommended stocks.
In addition to Kepler Capital , SAFRAN SA also received a Hold from UBS's Ian Douglas in a report issued yesterday. However, on the same day, Jefferies reiterated a Buy rating on SAFRAN SA (LSE: 0IU8).
Based on SAFRAN SA's latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of €13.29 billion and a net profit of €57 million. In comparison, last year the company earned a revenue of €11.13 billion and had a net profit of €1.86 billion
Based on the recent corporate insider activity of 22 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of 0IU8 in relation to earlier this year.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
3 hours ago
- Business Insider
Kepler Capital Reaffirms Their Hold Rating on Recordati Industria Chimica e Farmaceutica SPA (0KBS)
Kepler Capital analyst Niccolo Guido Storer maintained a Hold rating on Recordati Industria Chimica e Farmaceutica SPA (0KBS – Research Report) on May 14 and set a price target of €55.50. The company's shares closed last Wednesday at €50.30. Confident Investing Starts Here: Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter According to TipRanks, Guido Storer is a 5-star analyst with an average return of 16.6% and a 57.72% success rate. The word on The Street in general, suggests a Hold analyst consensus rating for Recordati Industria Chimica e Farmaceutica SPA with a €54.38 average price target, which is an 8.11% upside from current levels. In a report released on May 6, Deutsche Bank also maintained a Hold rating on the stock with a €55.00 price target.
Yahoo
14 hours ago
- Yahoo
Global's Top Penny Stocks To Watch In June 2025
Global markets have been navigating a complex landscape, with U.S. stocks showing resilience amid trade policy uncertainties and inflation easing to its slowest pace in four years. Against this backdrop, investors might find opportunities in penny stocks—an investment area that, despite its somewhat outdated name, remains relevant for those seeking growth potential in smaller or newer companies. These stocks can offer surprising value when backed by strong financial health, presenting a mix of value and growth that larger firms might overlook. Name Share Price Market Cap Financial Health Rating EZZ Life Science Holdings (ASX:EZZ) A$1.50 A$71.94M ★★★★★★ Lever Style (SEHK:1346) HK$1.14 HK$725.59M ★★★★★★ Foresight Group Holdings (LSE:FSG) £3.96 £445.67M ★★★★★★ Angler Gaming (NGM:ANGL) SEK3.61 SEK270.7M ★★★★★★ CNMC Goldmine Holdings (Catalist:5TP) SGD0.44 SGD178.33M ★★★★★☆ Southern Cross Electrical Engineering (ASX:SXE) A$1.67 A$453.46M ★★★★★★ Tasmea (ASX:TEA) A$3.08 A$716.16M ★★★★★☆ Yangzijiang Shipbuilding (Holdings) (SGX:BS6) SGD2.31 SGD9.09B ★★★★★☆ Bosideng International Holdings (SEHK:3998) HK$4.39 HK$50.15B ★★★★★★ Croma Security Solutions Group (AIM:CSSG) £0.86 £11.84M ★★★★★★ Click here to see the full list of 5,587 stocks from our Global Penny Stocks screener. We'll examine a selection from our screener results. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Shenzhen Asia Link Technology Development Co., Ltd. operates in the technology sector with a market capitalization of CN¥1.66 billion. Operations: No specific revenue segments have been reported for this company. Market Cap: CN¥1.66B Shenzhen Asia Link Technology Development Co., Ltd. is navigating the penny stock landscape with a market cap of CN¥1.66 billion, demonstrating resilience through its substantial cash runway exceeding three years at current free cash flow levels. Despite being unprofitable with negative return on equity, it has reduced losses by 24.7% annually over five years and boasts a seasoned management team and board of directors. Recent earnings reveal improved financial performance, with Q1 2025 revenues rising to CN¥104.95 million from CN¥83.29 million year-over-year, indicating potential growth amidst existing short-term liabilities challenges and stable debt levels relative to assets. Unlock comprehensive insights into our analysis of Shenzhen Asia Link Technology DevelopmentLtd stock in this financial health report. Gain insights into Shenzhen Asia Link Technology DevelopmentLtd's past trends and performance with our report on the company's historical track record. Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: Guizhou Bailing Group Pharmaceutical Co., Ltd. operates in the pharmaceutical industry, focusing on the development, production, and sale of traditional Chinese medicine products, with a market cap of CN¥5.65 billion. Operations: No specific revenue segments have been reported for the company. Market Cap: CN¥5.65B Guizhou Bailing Group Pharmaceutical Co., Ltd. is navigating financial challenges with a market cap of CN¥5.65 billion, having recently turned profitable despite a significant earnings decline over five years. The company reported Q1 2025 revenues of CN¥760.59 million, down from the previous year, and net income of CN¥24.17 million. Its debt management shows improvement with a reduced debt-to-equity ratio and satisfactory net debt levels supported by operating cash flow covering 23% of its debt. However, short-term liabilities match short-term assets, posing liquidity concerns amidst stable weekly volatility and experienced management oversight. Jump into the full analysis health report here for a deeper understanding of Guizhou Bailing Group Pharmaceutical. Examine Guizhou Bailing Group Pharmaceutical's past performance report to understand how it has performed in prior years. Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: Hainan RuiZe New Building Material Co., Ltd operates in China, focusing on the production and sale of commercial concrete and municipal sanitation services, with a market cap of CN¥3.98 billion. Operations: The company generates revenue primarily from its operations in China, amounting to CN¥1.23 billion. Market Cap: CN¥3.98B Hainan RuiZe New Building Material Co., Ltd, with a market cap of CN¥3.98 billion, faces financial challenges as it remains unprofitable with increasing losses over the past five years. Despite reporting sales of CN¥1.28 billion for 2024, revenue declined from the previous year, and net losses persisted at CN¥241.53 million. The company's high net debt to equity ratio of 175.8% raises concerns about its financial leverage, although it maintains a stable cash runway due to positive free cash flow growth. Additionally, short-term assets exceed both short and long-term liabilities, providing some balance sheet strength amidst volatility stability. Navigate through the intricacies of Hainan RuiZe New Building MaterialLtd with our comprehensive balance sheet health report here. Learn about Hainan RuiZe New Building MaterialLtd's historical performance here. Take a closer look at our Global Penny Stocks list of 5,587 companies by clicking here. Contemplating Other Strategies? Explore 22 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SZSE:002316 SZSE:002424 and SZSE:002596. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
Yahoo
16 hours ago
- Yahoo
3 Promising UK Penny Stocks With Market Caps Over £50M
The UK market has recently faced challenges, with the FTSE 100 index faltering due to weak trade data from China, highlighting global economic interdependencies. Despite these broader market pressures, certain investment opportunities remain attractive. Penny stocks, although an outdated term, continue to represent smaller or less-established companies that can offer value and growth potential when backed by strong financials. In this article, we will explore three such UK penny stocks that stand out for their financial health and potential for future growth. Name Share Price Market Cap Financial Health Rating Foresight Group Holdings (LSE:FSG) £3.96 £445.67M ★★★★★★ Warpaint London (AIM:W7L) £4.55 £367.58M ★★★★★★ Cairn Homes (LSE:CRN) £1.86 £1.16B ★★★★★☆ Van Elle Holdings (AIM:VANL) £0.365 £39.49M ★★★★★★ Helios Underwriting (AIM:HUW) £2.34 £169.52M ★★★★★☆ Polar Capital Holdings (AIM:POLR) £4.345 £418.91M ★★★★★★ LSL Property Services (LSE:LSL) £2.88 £297.56M ★★★★★☆ Begbies Traynor Group (AIM:BEG) £1.04 £165.92M ★★★★★★ Croma Security Solutions Group (AIM:CSSG) £0.86 £11.84M ★★★★★★ Braemar (LSE:BMS) £2.31 £72.32M ★★★★★★ Click here to see the full list of 401 stocks from our UK Penny Stocks screener. Let's take a closer look at a couple of our picks from the screened companies. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Iofina plc, with a market cap of £50.27 million, explores, develops, and produces iodine and halogen-based specialty chemical derivatives from oil and gas operations in the United States and the United Kingdom. Operations: The company's revenue is primarily generated from halogen derivatives and iodine, amounting to $54.47 million. Market Cap: £50.27M Iofina plc, with a market cap of £50.27 million, is positioned within the penny stock segment due to its valuation and operational scale. The company reported revenue of US$54.47 million for 2024, showing modest growth from the previous year but faced a decline in net income to US$2.92 million from US$6.56 million. Despite stable weekly volatility and high-quality earnings, Iofina's profit margins have decreased significantly over the past year, and it lowered its iodine production guidance for early 2025. However, strong asset coverage and reduced debt levels enhance its financial resilience amidst these challenges. Jump into the full analysis health report here for a deeper understanding of Iofina. Evaluate Iofina's prospects by accessing our earnings growth report. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Ramsdens Holdings PLC provides diversified financial services both in the United Kingdom and internationally, with a market capitalization of £112.70 million. Operations: Ramsdens Holdings PLC does not report specific revenue segments. Market Cap: £112.7M Ramsdens Holdings PLC, with a market cap of £112.70 million, demonstrates robust financial health within the penny stock category. The company reported half-year sales of £51.6 million and net income of £4.43 million, up from the previous year, indicating strong earnings growth. Its seasoned management team has overseen an increase in net profit margins and a stable debt profile supported by more cash than total debt. Recent announcements include plans to expand store openings and an increased interim dividend by 25% to 4.5 pence per share, highlighting its commitment to shareholder returns amidst ongoing business expansion efforts. Take a closer look at Ramsdens Holdings' potential here in our financial health report. Understand Ramsdens Holdings' earnings outlook by examining our growth report. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Focusrite plc develops, manufactures, and markets professional audio and electronic music products globally, with a market cap of £105.52 million. Operations: The company's revenue is derived from various segments, including Focusrite (£61.79 million), Novation (£17.07 million), ADAM Audio (£24.972 million), Martin Audio (£46.38 million), Sequential (£10.418 million), and Sonnox (£1.917 million). Market Cap: £105.52M Focusrite plc, with a market cap of £105.52 million, shows mixed signals in the penny stock arena. While earnings are forecast to grow at 35% annually, recent net profit margins have declined from 7% to 1.2%. The company's revenue for the first half of 2025 increased to £80.91 million from £76.88 million a year prior, but net income decreased to £1.84 million from £2.47 million. Despite high volatility and low return on equity (1.7%), Focusrite maintains satisfactory debt levels and strong short-term asset coverage over liabilities, supporting its financial stability amidst fluctuating performance metrics. Dive into the specifics of Focusrite here with our thorough balance sheet health report. Learn about Focusrite's future growth trajectory here. Investigate our full lineup of 401 UK Penny Stocks right here. Interested In Other Possibilities? Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 24 best rare earth metal stocks of the very few that mine this essential strategic resource. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include AIM:IOF AIM:RFX and AIM:TUNE. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
